Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 152 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Red Clear all

Conditions: Photodamage, Irregular Pigmentation, Acne Scars
Interventions: RevLite laser treatment, Fractionated Laser treatment; Procedure
Lead sponsor: ConBio, a Cynosure Company; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Erythema Nodosum Leprosum
Interventions: Dovramilast, Prednisolone, Thalidomide; Drug
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Phototherapy
Interventions: LED phototherapy, narrowband UVB phototherapy; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions: LED-RL phototherapy, Mock irradiation; Device
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Posterior Blepharoconjunctivitis
Interventions: Azithromycin ophthalmic solution, 1%; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stevens-Johnson Syndrome, Corneal Blindness
Interventions: Infliximab; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions: Alefacept; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Participants and/or Patients
Interventions: Psoriashield in the presence of a non-UV absorbing block., Psoriashield in the presence of a UV absorbing block., Psoriashield, Xtrac laser in the presence of a non-UV absorbing block., Xtrac in the presence of a UV absorbing block., Xtrac laser; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Acne Vulgaris
Interventions: Red Light (PDT); Drug
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Ostomy - Ileostomy or Colostomy, Stoma Complications, Stoma Site Dermatitis, Stoma Site Infection, Peristomal Wound Infection, Peristomal Skin Complication, Stomal Bleeding, Stoma Site Incisional Hernia, Retraction of Colostomy, Retraction of Ileostomy, Stoma Malfunction
Interventions: Chromic Gut Suture, Polyglactin 910 Suture; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-melanomatous Skin Cancer
Interventions: celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Erythema
Interventions: MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Pressure Ulcers, Tissue Injury
Interventions: Not listed
Lead sponsor: Trillennium Medical Imaging, Inc.; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Conditions: Obesity, Body Weight, Fat Burn, Cellulite, Abdominal Fat, Adipose Tissue Atrophy
Interventions: Care as Usual Group, Sham Group; Device
Lead sponsor: IR Technology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Hixson, Tennessee

Conditions: Southern Tick-Associated Rash Illness
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post Procedural Erythema
Interventions: Not listed
Lead sponsor: Acorn Biolabs Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 24 more

Conditions: Rosacea
Interventions: Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Skin Neoplasms
Interventions: aminolevulinic acid hydrochloride gel, 10%, aminolevulinic acid HCl topical solution, 20%; Combination Product
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 35 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Parvovirus B19 Infection
Interventions: VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas

Conditions: Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions: Adalimumab Injection; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erythema Migrans Lesions, Erythema Migrans
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immune System and Related Disorders
Interventions: Ibuprofen, Compound Exercise of Push-ups, oral placebo; Drug · Behavioral
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Bragg, North Carolina

Conditions: SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 10 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

Validation of a New Hand Held Light Emitting Diode Device for the Determination of Minimal Erythema Dose (MED)

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

MED in UVB Devices in the Presence and Absence of UV Filter

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

Suture Choice for Ostomy Creation

Celecoxib in Preventing Skin Cancer

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

The Analysis of Skin Temperature by Long Wave Infrared Imaging to Determine Its Effectiveness as a Predictor of Tissue Injury

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss

Investigation of Southern Tick-Associated Rash Illness (STARI)

Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities

B-19 Parvovirus Vaccine Study

Subconjunctival Humira for Boston Keratoprosthesis

Analysis of Lyme Disease Lesions

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)